OBJECTIVE: The objective was to investigate the effects of 3 years of growth hormone (GH) replacement therapy in GH deficient (GHD) patients in Sweden. DESIGN AND PATIENTS: An open label study in 237 adults with GHD (116 men and 121 women), consecutively enrolled in KIMS (Pfizer's international metabolic database) in Sweden. MEASUREMENTS: QoL and healthcare consumption were determined using questionnaires [QoL-assessment of GHD in Adults (QoL-AGHDA), the psychological general well-being (PGWB) index and the patient life situation form (PLSF)]. RESULTS: The mean starting dose of GH was 0.13 mg/day and the mean maintenance dose was 0.37 mg/day. The mean insulin-like growth factor I (IGF-I) SD score increased from -1.92 at baseline to 0.38 after 3 years. There was a sustained increase in QoL as measured by the QoL-AGHDA and PGWB questionnaires. The number of doctor visits and the number of days in hospital were reduced after 3 years of GH replacement. The number of days of sickleave decreased during the first 2 years of treatment, but returned towards baseline values after 3 years. Leisure-time physical activity and satisfaction with physical activity increased. CONCLUSION: Three years of GH replacement therapy induced a sustained improvement in QoL. Healthcare consumption was reduced, although the reduction in the number of days of sickleave was not statistically significant after 3 years of treatment.
OBJECTIVE: The objective was to investigate the effects of 3 years of growth hormone (GH) replacement therapy in GH deficient (GHD) patients in Sweden. DESIGN AND PATIENTS: An open label study in 237 adults with GHD (116 men and 121 women), consecutively enrolled in KIMS (Pfizer's international metabolic database) in Sweden. MEASUREMENTS: QoL and healthcare consumption were determined using questionnaires [QoL-assessment of GHD in Adults (QoL-AGHDA), the psychological general well-being (PGWB) index and the patient life situation form (PLSF)]. RESULTS: The mean starting dose of GH was 0.13 mg/day and the mean maintenance dose was 0.37 mg/day. The mean insulin-like growth factor I (IGF-I) SD score increased from -1.92 at baseline to 0.38 after 3 years. There was a sustained increase in QoL as measured by the QoL-AGHDA and PGWB questionnaires. The number of doctor visits and the number of days in hospital were reduced after 3 years of GH replacement. The number of days of sickleave decreased during the first 2 years of treatment, but returned towards baseline values after 3 years. Leisure-time physical activity and satisfaction with physical activity increased. CONCLUSION: Three years of GH replacement therapy induced a sustained improvement in QoL. Healthcare consumption was reduced, although the reduction in the number of days of sickleave was not statistically significant after 3 years of treatment.
Authors: Haroon Hasan; Fuchsia Howard; Steven G Morgan; Daniel L Metzger; Andrea C Lo; Karen Goddard; Sabrina Gill; Michelle Johnson Journal: Healthc Policy Date: 2014-02
Authors: Charles W Wilkinson; Kathleen F Pagulayan; Eric C Petrie; Cynthia L Mayer; Elizabeth A Colasurdo; Jane B Shofer; Kim L Hart; David Hoff; Matthew A Tarabochia; Elaine R Peskind Journal: Front Neurol Date: 2012-02-07 Impact factor: 4.003
Authors: Kristian Bolin; Rickard Sandin; Maria Koltowska-Häggström; Jane Loftus; Christin Prütz; Björn Jonsson Journal: Cost Eff Resour Alloc Date: 2013-09-30
Authors: Merel van der Meulen; Amir H Zamanipoor Najafabadi; Leonie H A Broersen; Jan W Schoones; Alberto M Pereira; Wouter R van Furth; Kim M J A Claessen; Nienke R Biermasz Journal: J Clin Endocrinol Metab Date: 2022-04-19 Impact factor: 6.134
Authors: Carolyn V McMillan; Clare Bradley; James Gibney; David L Russell-Jones; Peter H Sönksen Journal: Health Qual Life Outcomes Date: 2006-03-22 Impact factor: 3.186